Detailed Narrative
Robust Q4 Performance Across Segments
Biocon delivered a strong Q4 FY25, with overall revenue from operations reaching INR 4,417 crores, marking a 15% year-over-year and 16% sequential growth on a like-for-like basis. This growth was broad-based, with Generics surging 46% YoY, Biosimilars growing 9% YoY, and Research Services (Syngene) expanding 11% YoY. The group's core EBITDA stood at INR 1,363 crores, a 16% increase YoY, achieving a healthy 31% operating margin.
Strategic Product Launches and Approvals
The quarter was marked by significant advancements in Biocon's product portfolio. Key highlights included the global launch of Liraglutide in the U.K. and the introduction of Lenalidomide and Dasatinib in the U.S. Notably, Yesintek™ (biosimilar Ustekinumab) was successfully launched in the U.S., securing over 70% market access with payers and covering over 100 million lives, becoming the fifth product from Biocon's portfolio to enter the U.S. market.
Biosimilars Momentum and Pipeline
Biocon Biologics demonstrated strong commercial momentum, with Fulphila® (Pegfilgrastim) and Ogivri® (Trastuzumab) achieving U.S. market shares of 30% and 26% respectively, a two-fold increase from the previous year. The company secured U.S. FDA approval for Jobevne™ (biosimilar Bevacizumab) and received a positive EU CHMP opinion for biosimilar Denosumab, with U.S. approval expected by year-end. The settlement with Regeneron secured a U.S. market entry for Yesafili™ (biosimilar Aflibercept) no later than H2 2026, with a Canada launch slated for July 2025.
Generics Business Growth and Future Drivers
The Generics business recorded its strongest quarter in FY25, with revenue reaching INR 1,048 crores, driven primarily by the launch quantities of Lenalidomide. While FY25 Generics EBITDA margin was 12% due to pricing pressure and new plant capitalizations, future growth is expected from upcoming launches like Liraglutide in Europe (Q2 FY26) and the U.S. (H2 calendar year), as well as generic Copaxone and Everolimus in the U.S. Tacrolimus supplies to China commenced, with commercialization expected in Q1 FY26.
Capital Allocation and Funding Strategy
Biocon announced plans to raise INR 4,500 crores through a combination of QIP and private placement, with the first tranche expected by mid-June. These proceeds will primarily be used to meet financial obligations related to structured debt for Biocon Biologics. The company's net debt stood at USD 1.1 billion (USD 1.2 billion normalized) as of March 31, 2025, with net inventory at USD 390 million and receivables around 90 days, indicating improved working capital management.
Strategic Review and GLP-1 Investments
In response to market volatility🌐, the Board has constituted a committee to evaluate strategic options, including a possible merger of Biocon Limited and Biocon Biologics Limited, with an update expected in a few months. The company has also made significant investments in GLP-1s, capitalizing a large-scale drug substance capacity in FY25 and commissioning a new injectable facility in FY26, positioning itself to address the substantial market opportunity for drugs like Semaglutide (off-patent 2031) and Tirzepatide (after 2036).
Syngene's Expansion and Performance
Syngene International achieved a milestone, with its Q4 revenue crossing INR 1,000 crores for the first time, reaching INR 1,018 crores, an 11% YoY increase. Its EBITDA for the quarter was INR 363 crores, with a 35% margin. The acquisition of a biologics manufacturing facility in the U.S. further enhances Syngene's capabilities in the global CRDO market and establishes its first U.S. manufacturing footprint.